REG - Immupharma PLC - Notice of AGM & Annual Report & Accounts

ImmuPharmaAnnouncement

02/06/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260602:nRSB5241Ga&default-theme=true

RNS Number : 5241G  Immupharma PLC  02 June 2026

 

 

 

 

RNS:
RELEASE
2 June 2026

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Notice of AGM & Annual Report & Accounts

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, confirms that the Notice of Annual General Meeting ("AGM") has today
been posted to shareholders. The Annual Report and Accounts for the year ended
31 December 2025 has also been posted to shareholders today.

 

These documents will be available shortly, in electronic form, for download on
the Company's website www.immupharma.co.uk (http://www.immupharma.co.uk) .

 

ImmuPharma's AGM will be held on Thursday 25th June 2026 @ 11:00am (BST) at
the offices of Broadfield Law UK LLP, One Bartholomew Close, London EC1A 7BL.

Ends

 ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )
 Tim McCarthy, Chief Executive Officer and Chairman

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 8974 (tel:0113%20370%208974)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 203 650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

 

The lead program, P140, is a unique non-immunosuppressive peptide for the
treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic
Demyelinating Polyneuropathy) and preclinical models suggest therapeutic
activity for many other autoimmune diseases. Kapiglucagon is being developed
for the treatment of type 1 diabetes.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk/) .

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSZFLFBQQLXBBD



            Copyright 2019 Regulatory News Service, all rights reserved